评估对第三代头孢菌素不敏感的预测因素,以及影响由自由柠檬酸杆菌复合体、丁香杆菌复合体和产气克雷伯菌引起的菌血症中复发或死亡的因素。

IF 1.9 4区 医学 Q3 INFECTIOUS DISEASES
Journal of Chemotherapy Pub Date : 2024-11-01 Epub Date: 2024-03-07 DOI:10.1080/1120009X.2024.2323326
Kazuhiro Kobayashi, Atsuko Hata, Waki Imoto, Shigeki Kakuno, Wataru Shibata, Koichi Yamada, Hiroshi Kawaguchi, Norihiro Sakurai, Toshikazu Ito, Kazuya Uenoyama, Tamotsu Takahashi, Satoru Ueda, Toshiro Katayama, Masahide Onoue, Hiroshi Kakeya
{"title":"评估对第三代头孢菌素不敏感的预测因素,以及影响由自由柠檬酸杆菌复合体、丁香杆菌复合体和产气克雷伯菌引起的菌血症中复发或死亡的因素。","authors":"Kazuhiro Kobayashi, Atsuko Hata, Waki Imoto, Shigeki Kakuno, Wataru Shibata, Koichi Yamada, Hiroshi Kawaguchi, Norihiro Sakurai, Toshikazu Ito, Kazuya Uenoyama, Tamotsu Takahashi, Satoru Ueda, Toshiro Katayama, Masahide Onoue, Hiroshi Kakeya","doi":"10.1080/1120009X.2024.2323326","DOIUrl":null,"url":null,"abstract":"<p><p>Factors involved in the susceptibility of third-generation cephalosporins (3GCs) to bacteremia caused by <i>Citrobacter freundii</i> complex, <i>Enterobacter cloacae</i> complex, and <i>Klebsiella aerogenes</i> were investigated based on a case-case-control design. Antimicrobial therapy administered 30 days prior to bacteremia and hospitalization within 90 days were common risk factors for the 3GC susceptible and 3GC non-susceptible groups, while hospitalization from an institution or another hospital was a specific risk factor for the 3GC non-susceptible group. We also attempted to examine the factors affecting the clinical outcome of bacteremia. Hospitalization more than 14 days before the onset of bacteremia was an independent factor indicating poor clinical outcome. In contrast, the implementation of source control was an independent predictor of successful treatment. Although a longer hospital stay before the onset of bacteremia was associated with worse clinical outcomes, implementation of source control may have contributed to improved treatment outcomes for bacteremia.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"521-531"},"PeriodicalIF":1.9000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Evaluation of predictors of third-generation cephalosporin non-susceptibility and factors affecting recurrence or death in bacteremia caused by <i>Citrobacter freundii</i> complex<i>, Enterobacter cloacae</i> complex, and <i>Klebsiella aerogenes</i>.\",\"authors\":\"Kazuhiro Kobayashi, Atsuko Hata, Waki Imoto, Shigeki Kakuno, Wataru Shibata, Koichi Yamada, Hiroshi Kawaguchi, Norihiro Sakurai, Toshikazu Ito, Kazuya Uenoyama, Tamotsu Takahashi, Satoru Ueda, Toshiro Katayama, Masahide Onoue, Hiroshi Kakeya\",\"doi\":\"10.1080/1120009X.2024.2323326\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Factors involved in the susceptibility of third-generation cephalosporins (3GCs) to bacteremia caused by <i>Citrobacter freundii</i> complex, <i>Enterobacter cloacae</i> complex, and <i>Klebsiella aerogenes</i> were investigated based on a case-case-control design. Antimicrobial therapy administered 30 days prior to bacteremia and hospitalization within 90 days were common risk factors for the 3GC susceptible and 3GC non-susceptible groups, while hospitalization from an institution or another hospital was a specific risk factor for the 3GC non-susceptible group. We also attempted to examine the factors affecting the clinical outcome of bacteremia. Hospitalization more than 14 days before the onset of bacteremia was an independent factor indicating poor clinical outcome. In contrast, the implementation of source control was an independent predictor of successful treatment. Although a longer hospital stay before the onset of bacteremia was associated with worse clinical outcomes, implementation of source control may have contributed to improved treatment outcomes for bacteremia.</p>\",\"PeriodicalId\":15338,\"journal\":{\"name\":\"Journal of Chemotherapy\",\"volume\":\" \",\"pages\":\"521-531\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Chemotherapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/1120009X.2024.2323326\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/3/7 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1120009X.2024.2323326","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/7 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

摘要

通过病例-病例对照设计,研究了第三代头孢菌素(3GC)对由弗氏柠檬酸杆菌复合菌、丁香杆菌复合菌和产气克雷伯菌引起的菌血症的敏感性相关因素。菌血症发生前 30 天接受抗菌治疗和 90 天内住院是 3GC 易感组和 3GC 非易感组的共同风险因素,而从其他机构或其他医院住院则是 3GC 非易感组的特定风险因素。我们还试图研究影响菌血症临床结果的因素。在菌血症发病前 14 天以上住院是表明临床结果不佳的一个独立因素。相比之下,实施源头控制是成功治疗的独立预测因素。虽然菌血症发病前住院时间较长与临床效果较差有关,但实施源头控制可能有助于改善菌血症的治疗效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Evaluation of predictors of third-generation cephalosporin non-susceptibility and factors affecting recurrence or death in bacteremia caused by Citrobacter freundii complex, Enterobacter cloacae complex, and Klebsiella aerogenes.

Factors involved in the susceptibility of third-generation cephalosporins (3GCs) to bacteremia caused by Citrobacter freundii complex, Enterobacter cloacae complex, and Klebsiella aerogenes were investigated based on a case-case-control design. Antimicrobial therapy administered 30 days prior to bacteremia and hospitalization within 90 days were common risk factors for the 3GC susceptible and 3GC non-susceptible groups, while hospitalization from an institution or another hospital was a specific risk factor for the 3GC non-susceptible group. We also attempted to examine the factors affecting the clinical outcome of bacteremia. Hospitalization more than 14 days before the onset of bacteremia was an independent factor indicating poor clinical outcome. In contrast, the implementation of source control was an independent predictor of successful treatment. Although a longer hospital stay before the onset of bacteremia was associated with worse clinical outcomes, implementation of source control may have contributed to improved treatment outcomes for bacteremia.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Chemotherapy
Journal of Chemotherapy 医学-药学
CiteScore
3.70
自引率
0.00%
发文量
144
审稿时长
6-12 weeks
期刊介绍: The Journal of Chemotherapy is an international multidisciplinary journal committed to the rapid publication of high quality, peer-reviewed, original research on all aspects of antimicrobial and antitumor chemotherapy. The Journal publishes original experimental and clinical research articles, state-of-the-art reviews, brief communications and letters on all aspects of chemotherapy, providing coverage of the pathogenesis, diagnosis, treatment, and control of infection, as well as the use of anticancer and immunomodulating drugs. Specific areas of focus include, but are not limited to: · Antibacterial, antiviral, antifungal, antiparasitic, and antiprotozoal agents; · Anticancer classical and targeted chemotherapeutic agents, biological agents, hormonal drugs, immunomodulatory drugs, cell therapy and gene therapy; · Pharmacokinetic and pharmacodynamic properties of antimicrobial and anticancer agents; · The efficacy, safety and toxicology profiles of antimicrobial and anticancer drugs; · Drug interactions in single or combined applications; · Drug resistance to antimicrobial and anticancer drugs; · Research and development of novel antimicrobial and anticancer drugs, including preclinical, translational and clinical research; · Biomarkers of sensitivity and/or resistance for antimicrobial and anticancer drugs; · Pharmacogenetics and pharmacogenomics; · Precision medicine in infectious disease therapy and in cancer therapy; · Pharmacoeconomics of antimicrobial and anticancer therapies and the implications to patients, health services, and the pharmaceutical industry.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信